Cencora, Inc. (COR) is a publicly traded Healthcare sector company. As of May 20, 2026, COR trades at $262.65 with a market cap of $50.95B and a P/E ratio of 20.19. COR moved -0.54% today. Year to date, COR is -22.34%; over the trailing twelve months it is -9.62%. Its 52-week range spans $218.65 to $377.54. Analyst consensus is strong buy with an average price target of $358.40. Rallies surfaces COR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cencora slides as Q2 adjusted EPS and cash flow miss overshadow raised outlook: Cencora shares fell after fiscal Q2 2026 results showed adjusted EPS of $4.75 on revenue of $78.4 billion, alongside sharply negative operating cash flow of $(966.5) million for the first six months. The company raised full-year adjusted EPS guidance to $17.65–$17.90, but investors focused on cash burn and a modest EPS shortfall versus roughly $4.80–$4.82 consensus.
| Metric | Value |
|---|---|
| Price | $262.65 |
| Market Cap | $50.95B |
| P/E Ratio | 20.19 |
| EPS | $13.12 |
| Dividend Yield | 0.60% |
| 52-Week High | $377.54 |
| 52-Week Low | $218.65 |
| Volume | 1.65M |
| Avg Volume | 0 |
| Revenue (TTM) | $328.68B |
| Net Income | $2.55B |
| Gross Margin | 3.81% |
11 analysts cover COR: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $358.40.